Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Everest Medicines Ltd. ( (HK:1952) ).
Everest Medicines has provided additional details on an asset purchase agreement involving an in-licensed paroxysmal supraventricular tachycardia (PSVT) treatment from a seller ultimately controlled by RTW Investments, LP’s managing partner Roderick Wong. The transaction includes assignment of key ancillary agreements with Milestone Pharmaceuticals that secure supply, safety data exchange and quality assurance, allowing Everest to assume the seller’s rights and obligations and maintain continuity of product commercialization.
The company said the deal consideration reflects the product’s FDA approval as the first and only self-administered nasal spray for converting PSVT to sinus rhythm in adults, and the sizeable, underserved Chinese PSVT market of an estimated 3 million to 6 million patients. With China’s drug regulator having accepted the new drug application in January 2025 and potential approval expected in the third quarter of 2026, Everest is positioning itself to capitalize on a differentiated, at-home therapy while managing regulatory and development risks through discounted pricing tied to probabilities of success and contractual payment exposures.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$55.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Limited is a biopharmaceutical company focused on licensing, developing and commercializing innovative therapies in Asia, with a particular emphasis on the China market. Its portfolio includes in-licensed assets targeting significant unmet medical needs, and it works with global partners to bring advanced treatments and novel drug delivery options to patients in the region.
Average Trading Volume: 2,863,898
Technical Sentiment Signal: Sell
Current Market Cap: HK$13.08B
For detailed information about 1952 stock, go to TipRanks’ Stock Analysis page.